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Release of platelet-activating factor, slow-reacting substance, and vaso-
active amines from isolated rat kidneys. The present work brings the first
evidence for the simultaneous release of Paf-acether (platelet-activating
factor), slow-reacting substance (SRS), histamine, and serotonin from
isolated rat kidneys stimulated with ionophore A 23187. However, with
compound 48/80 we detected only SRS, histamine, and serotonin. Upon
addition of antigen, kidneys from sensitized rats released Paf-acether
and SRS of anaphylaxis. Paf-acether released in the perfusate was
identified by its ability to aggregate aspirin-treated washed rabbit
platelets in the presence of an ADP scavenger complex. It was also
characterized by its inactivation by phospholipase A2, and it was eluted
from high pressure liquid chromatography (HPLC) after 16 to 18 mm, a
retention identical to that of synthetic Paf-acether, that is, between
sphingomyelin and lysophosphatidyicholine. The biological activity of
SRS was detected after several purification steps including Amberlite
XAD-2 and reverse phase HPLC (RP-HPLC). Kidney SRS exhibited a
typical spasmogenic activity in isolated guinea-pig ileum preparation
that was reversed by FPL 55712. When kidneys were incubated with
[3H]arachidonic acid, radioactivity and biological activity comigrated in
RP-HPLC with leukotrienes C and D. These results indicate that the
kidney is capable of actively released inflammatory mediators.
Liberation du platelet-active facteur, de Ia Ient-réagit substance, et
d'amines vasoactives, a partir de reins isolés de rats Nous avons mis en
evidence Ia Iib&ation de Paf-acdther (platelet-active facteur), lent-réagit
substance (SRS), histamine, et sérotonine par le rein de rat isolé et
stimulé par du ionophore A 23187. Une stimulation au 48/80 induit
seulement La liberation de Ia SRS, histamine, et sérotonine. En presence
de l'antigène, les reins de rats sensibilisés libèrent du Paf-acéther et de
Ia SRS. Le Paf-acéther renal a été caractérisé par sa capacité a agréger
les plaquettes Iavées de lapin en presence d'aspirine et du complexe
crCatine phosphate/créatine phosphokinase, son inactivation par Ia
phospholipase A2 de pancreas, et son temps de retention en chromato-
graphie liquide a haute pression (HPLC) entre Ia sphingomyéline et Ia
lysophosphatidyicholine, de 16 a 18 mm, identique a celui du Paf-
acéther synthetique. La SRS a été détectée aprés purification sur
colonne d'Amberlite XAD-2 et par HPLC en phase reverse (RP-
HPLC). Elle a été caractérisée par sa capacité a contracter I'iléon de
cobaye en presence d'atropine et d'antihistaminique, contraction qui
est relaxCe specifiquement par le FPL 55712, par son incorporation
d'acide arachidonique tritié et I'élution en RP-HPLC de Ia radioactivité
a des temps de retention identiques a ceux des leukotriènes C et D
synthétiques. Ces résultats démontrent que le rein est capable de libérer
des mediateurs de l'inflammation.
Paf-acether (platelet-activating factor), slow-reacting sub-
stance (SRS), histamine, and serotonin, are well known media-
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tors of immediate hypersensitivity and inflammation [1—4]. Paf-
acether is a l-0-alkyl-2-acetyl-glycero-sn-3-phosphocholine [5,
6] with potent platelet and neutrophil-activating properties [1, 7,
8].
SRS, a family of lipoxygenase-dependent arachidonic acid
(AA) metabolites, is now identified as leukotrienes C and D
which exhibit potent spasmogenic activity on several smooth
muscles [9, 10]. Histamine and serotonin which, by contrast
with the latter substances, are preformed mediators released
from basophils, mast cells and platelets, produce smooth mus-
cle contraction and increase vascular permeability [3, 4]. Hista-
mine was also described to be synthesized by isolated glomeruli
and renal tubules [11]. The release of Paf-acether and SRS
appears to be mediated by a variety of immune and nonimmune
stimuli. Paf-acether was initially described as originating from
IgE-sensitized rabbit basophils [11 and later from various cell
types with proinflammatory properties [12]. SRS production
has also been obtained from these same cells [13—151 as well as
mast cells [16]. By contrast, little is known on the release of Paf-
acether and SRS from perfused organs in the absence of blood
cells [17, 18]. SRS was obtained from isolated perfused lungs
[17] and hearts [18]. The release of Paf-acether from isolated
perfused organs has not yet been reported. Since the kidney is a
target for several immunopathological conditions, it was of
interest to investigate whether it could release the four major
mediators of inflammation under several stimuli.
This paper describes the release of Paf-acether, SRS, hista-
mine, and serotonin, from isolated perfused rat kidneys stimu-
lated with the ionophore A 23187 (lo) and compound 48/80 (a
mast cell-degranulating agent). Paf-acether and SRS of anaphy-
laxis (SRS-A) were also released upon antigen (Ag) stimulation
from kidneys of immunized rats. The four mediators were
characterized by their biological effects. Paf-acether and SRS
were also characterized by physicochemical criteria.
Methods
Reagents. Sodium pentobarbital (Nembutal®) was from Ab-
bott (Chicago, Illinois), heparin from Roche (Neuilly-sur-Seine,
France) and lonophore A 23187 from Calbiochem (San Diego,
California). Compound 48/80, histamine, serotonin, creatine
phosphate, creatine phosphokinase, and essentially fatty acid
free bovine serum albumin (BSA), ovalbumin (Ov), ethylene
glyco-bis (/3-amino-ethyl ether), and N,N2-tetra-acetic acid
(EDTA) were from Sigma Chemical Company (St. Louis,
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Fig. 1. Biopsy from perfused rat kidney. A Normal renal parenchymal tissue. No blood cells are present within glomerular and intertubular
capillaries. (Light microscopy, x300) B Normal endothelial cell (EC). Podocyte (P) and a portion of capillary loop are surrounded by normal
basement membrane (BM). Podocyte extensions are well differentiated. (Electron microscopy, x6250)
Missouri). Lysine acetyl salicylate (Aspegic®) was from Labo-
ratory Egic (Amilly, France). Atropine and pyrilamine maleate
were from ICN (Plainview, New York). Methysergide was
purchased from Sandoz S.A. (Base!, Switzerland), [3H]Inulin
from Amersham (Amersham, United Kingdom); [3H]AA (55.5
mCilmmole, sp act) was from New England Nuclear Corpora-
tion (Boston, Massachusetts). Estradiol was obtained from
Roussel (Paris, France), RPMI 1640 from Flow Laboratories
(Irvine, United Kingdom), lipase and phospholipase A2 from
Boehringer (Mannheim, Federal Republic of Germany), alumin-
ium hydroxide from Merck (Darmstadt, Federal Republic of
Germany), and complete adjuvant (Freund) from Biomérieux
(Marcy L'Etoile, France). Compound FPL 55712 was a gift
from Dr. Phil Sheard, Fisons Labs (Loughborough, United
Kingdom) and leukotrienes C and D were a gift from Dr. Joshua
Rokach, Merck-Frosst (Montreal, Canada). Synthetic PAF-
acether was a gift from Prof. Jean J. Godfroid (Université Paris
VII, France).
Buffers. We used the following buffers in millimolar concen-
trations: Tyrode's gelatin buffer: KCI, 2.6; MgCI2, 1; NaCl, 137;
NaHCO3, 1.2; glucose, 5.4; EGTA, 0.2. This buffer was supple-
mented with gelatin (2.5 g/liter). Tyrode's gelatin solution with
Tris, 10 nM, instead of bicarbonate, contained CaCI2, 1.3, and
no EGTA. Jalon's buffer contained NaCl, 15; KCI, 5.6; Ca2CI,
0.4; NaHCO3, 6; and glucose, 2.7. Krebs solution contained
NaC1, 11; NaHCO3, 20; MgSO4, 0.12; KH2PO4, 10; CaCl2, 2.5;
glucose, 5.5, supplemented with 0.25% bovine serum albumin
(K-BSA).
Kidney perfusion procedure. The perfusion apparatus used in
these experiments was similar to that described by Bowman
and Maack [19] modified by Nakane et al [20]. This apparatus
was composed of a central glass column and a secondary
column containing K-BSA gassed with a mixture of 95% 02 and
5% CO2 constantly recirculated by a pump (Cole-Parmer,
Chicago, Illinois). Before use, the perfusate was filtered
through a 0.50 m filter (Millipore Corp., Bedford, Massachu-
setts). Male Wistar rats or Brown Norway (BN) rats weighing
300 to 350 g were anesthetized with an intraperitoneal injection
of pentobarbital (40 mg/kg). Heparin (200 U) was injected into
the right jugular vein and a laparotomy was performed. The
right ureter was cannulated with a polyethylene tubing (ID 28
mm, OD 61 mm) (Clay-Adams, Parsippany, New Jersey). The
right renal artery was then cannulated with a needle (0.8 x 38
mm) through the superior mesenteric artery, and the kidney
was continuously perfused in situ with K-BSA introduced
through the secondary column. Thereafter the kidney was taken
out en bloc and rinsed with 30 ml of K-BSA through the same
column. It was then transferred into the central column and
allowed to equilibrate in pressure and flow rate for 15 to 30 mm.
During the equilibration period, a sample was collected every
w
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Paf-acether
ng
Histamine Serotonin
ag
IonophoreA23l87 17.6 3.2 292.7 32.3 1.35 0.32
(2.5 ctg/ml)
48/80 Compound 0 220.0 11.2 1.36 0.27
(10 j.g/mI)
Ovalbumin6 3.7 0.5 ND ND
(1 mg/mI)
Ovalbumin° 1.5 0.3 ND ND
(1 mg/mI)
a Values are the mean I SD of six experiments. Agonists were
introduced in the central column of the perfusion apparatus. Mediators
were assayed after I hr perfusion.
b Rats were either immunized with 5 mg Ovalbumin in complete
Freund's adjuvant or with I zg of Ovalbumin and 10 mg of aluminium
hydroxide.
15 mm. The stimulating agents, lo (2.5 .tg/ml), compound 48/80
(10 j.g/ml), or Ov (1 mglml), or the diluting fluid alone was then
introduced in the central column. Samples (1 ml) were collected
at every 2-mm interval for 10 mm and thereafter every 10 mm
until 60 mm, the end of the experiment. To study the release of
Paf-acether in a "single pass" perfusion, the kidney perfusion
was performed outside the central column. lo was added to the
buffer and fractions were collected at 1-mm intervals using an
(ISCO, Lincoln, Nebraska) automated fractionator. Urinary
samples were collected at 30-mm intervals. Samples were kept
at —20°C until Paf-acether and SRS assay. To preserve hista-
mine and serotonin, some samples were immediately added
with 20 d HCL 1 N and brought to neutrality with NaOH before
biological assay. When histamine was assayed by the spectro-
fluorometric method (see below), 1 ml of 0.8 N perchlonc acid
was added to 1 ml of perfusate. One hour later the mixture was
centrifuged at x 2800g for 15 mm. Supernatants were stored at
4°C in polystyrene tubes until the assay. To measure the
residual histamine and serotonin, the kidneys were removed at
the end of the perfusion, rapidly minced, and homogenized with
a blade homogenizer either in 4 ml 0.4 N perchloric acid or 1 N
HCI for histamine or serotonin assay, respectively. After 1-hr
incubation the samples were centrifuged at x 2800g for 15 mm
and the supernatants were stored at 4°C in polystyrene tubes
until the assay.
At the end of the experiments, the remaining eluate was
centrifuged at x400g for 15 mm. The pellet was recovered in
100 d of K buffer and cells were counted on a hemocytometer.
In six experiments, GFR was measured at the addition of
[3H]Inulin (2.5 1iCi) to the 80 ml of perfusate as in [191; the GFR
is expressed as ml/min/g of wet kidney.
Immunization. Six of the 12 male BN rats used were subcuta-
neously injected with I .tg Ov in 10 mg aluminium hydroxide.
The other six rats were injected with 5 mg Ov in complete
Freund's adjuvant. Both groups of rats were boosted with the
same dose of antigen 2 weeks later. Kidney perfusion took
place 1 week after the second injection.
Mediator assays, Paf-acether was measured by aggregation
of washed rabbit platelets obtained as described in [11, pretreat-
ed with aspirin (0.1 mM), a cyclooxygenase blocker. Aggrega-
tion took place in Tyrode's gelatin containing creatine phos-
Fig. 2. Kinetics of Paf-acether released from perfused rat kidney upon
stimulation with Jo (2.5 g/ml) •—•, and 48/80 compound (10
ag/ml) +—•. Each point represents the mean 1 SD of six
experiments. Kinetics of Paf-acether released upon lo stimulation in a
"single pass" perfusion with nonrecirculating buffer are designated by
0-0-0 (N = 3).
phate (0.7 mM) and creatine phosphokinase (1.9 U/mI), an
adenosine diphosphate scavenger complex. The assay was
performed in an aggregometer (Icare, Marseille, France). The
amount of Paf-acether released is expressed in nanograms by
comparison with totally synthetic Paf-acether [21]. Paf-acether
was also characterized by the abolition of its aggregating
activity upon incubation with 10 ig/m1 phospholipase A2 from
hog pancreas, its insensitivity to 100 .tg/ml lipase from Rhizo-
pus arrhizus, or to acid hydrolysis in trichloroacetic acid 0.3 N
in methanol. These methods have been published elsewhere in
detail [21]. SRS was assessed on a guinea-pig ileum as previous-
ly described [22]. Briefly, 2 cm of terminal ileum were set in a
37°C chamber bath containing 3.5 ml of Tyrode's solution
gassed with 100% 02 and supplemented with 0.5 tM atropine
(an anticholinergic antagonist), 1 JiM pyrilamine (an antagonist
of histamine), and I JiM methysergide (an antagonist of seroto-
nm). The contractions induced by SRS were specifically re-
versed by the compound FPL 55712 (1 JigIml). Results are
expressed in SRS units as defined by Orange et al [22].
Serotonin was measured by the contraction of the rat uterus
according to previously published methods [23]. Female Wistar
rats were injected subcutaneously with estradiol (0.1 mg/kg) 18
to 20 hr before the assay. A uterine horn was removed, washed
in cold (4°C) Jalon's solution, cut longitudinally, and placed in a
bath containing Jalon's solution gassed with 100% 02. Tissue
samples were allowed to equilibrate for 1 hr. In all experiments
serotonin-induced contractions were assessed by using the
specific antagonist methysergide (1 JiM). Results were ex-
pressed in micrograms per milliliter by comparison with stan-
dard serotonin contractions. For both SRS and serotonin bioas-
says, contractions were measured using an isometric transducer
(F60-Narco, Houston, Texas) and were recorded on a physio-
graph (MK IV, Narco).
Histamine was assayed by the modification of the fluoromet-
ric method [24] adapted to automated continuous-flow tech-
nique. A linear relationship was obtained from 0 to 5 Jig/mI of
histamine base. Neither lo nor 48/80 compound influenced the
histamine fluorescence.
Chromatographic procedures for Paf-acether and SRS. Pro-
teins contained in the eluate of one perfused kidney were
allowed to precipitate during 30 mm at 22°C upon the addition of
Table 1. Total amounts of Paf-acether, histamine, and serotonin
recovered from perfused kidneya
a)
AZ
a)0
9i
—30 —20 —10 0 2 4 8 20 40 60
Time, mm
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Fig. 3. HPLC elution profile of Paf-acether obtained from rat kidney
after Jo stimulation. Similar profiles of Paf-acether were obtained from
Ag-stimulated kidneys from immunized rats. Sphingomyelin (Sph),
lysophosphatidyicholine (LPC), and synthetic Paf-acether were used as
markers and chromatographed on the same day as kidney Paf-acether.
4 volumes of ethanol. After centrifugation (xllOOg for 15 mm),
the supernatant was collected and evaporated to dryness under
negative pressure. After recovery in chloroform, Paf-acether
was chromatographed on a silicic acid column developed by
stepwise elution by chloroform, chloroform methanol mixture,
and methanol, as previously described [211. The first 100%
methanol fraction was evaporated and the residue was recov-
ered in chloroformlmethanol (1:1, v/v) and further character-
ized by its retention time on a high pressure liquid chromatogra-
phy (HPLC) apparatus (Waters, Milford, Massachusetts), using
a Microporasil column eluted with dichloromethane:methanol:
water (60:50:5, v/v). The flow rate was 1.7 mllmin; fractions
were collected each minute. The fractions were dried under an
air stream. Paf-acether was recovered in 0.2 ml of RPMI-BSA
and bioassayed on platelets as described above. In these
experiments, kidney Paf-acether retention time was compared
to that of sphingomyelin, lysophosphatidyicholine, and synthet-
ic Paf-acether as described in [211.
For SRS chromatography, the dry ethanolic residue was
recovered in distilled water and desalted on Amberlite XAD-2
as in [24]. The 80% ethanolic eluate was evaporated, and the
residue was diluted with methanol and further characterized by
its retention time on a reverse phase HPLC (RP-HPLC). It was
carried out as in [25] using a Bondapak C18 column eluted with
a nonlinear gradient of methanol in water and monitored by a
720 programmer (Waters) with a flow rate of 1 mLlmin. Frac-
tions were dried under negative pressure. SRS was recovered in
distilled water (0.2 ml) before bioassay. Synthetic leukotrienes
LTC and LTD, [3H]PGE2, [3H]PGF2, and [3H]AA were used as
markers for the RP-HPLC procedures.
In four experiments, kidneys were perfused for 30 mm with 5
iCi of [3H]AA (55.5 mCilmmole). The kidney was then with-
drawn from the central column and continuously perfused for 5
mm through the secondary column to eliminate the nonfixed
Time, mm
Fig. 4. Elution pattern of kidney-derived SRS on reverse phase HPLC.
Elution was carried out with a discontinuous methanol:water gradient.
Contractile response is expressed in SRS units as defined in Methods.
AA. During this period, the central circuit was rinsed with
distilled water and re-equilibrated with 80 ml of K-BSA. The
kidney was then placed back in the central column. lo (2.5
.tg/ml) was added to the buffer, and the perfusion was continued
as described above.
Light and electron microscopy. For light microscopy, the
tissue was fixed in 15% formalin and embedded in paraffin.
Sections (2 to 3 ) were stained with either Masson's trichrome
stain (light green) or hematoxylin eosin and safran or periodic
acid Schiff and silver impregnation by Wilder's technique. For
electron microscopy, renal specimens were fixed in 2% glutar-
aldehyde, postfixed in 1% osmium tetroxide, embedded in
epoxy resin (Epon 812), and cut on a Reichert Ultra Microtome.
The ultra-thin sections were stained with uranyl acetate and
lead citrate.
Results
Morphological and physiological studies. The total perfusion
fluid contained 10,323 3,162 leukocytes (mean 1 SD of six
experiments). Ten sections from two perfused kidneys were
examined by either optical or electron microscopy. No blood
cells were found either in the glomeruli or elsewhere in the
kidney (Fig. 1). As a control for a functional kidney the GFRs
were determined in three experiments. We found for 0.23
0.04 mllmin/g 0 to 30 mm and 0.16 0.01 mllmin/g for 30 to 60
mm of perfusion.
Paf-acether release and characterization. Paf-acether was
released at the addition of Jo to the perfusion system (Table 1).
Kinetics of Paf-acether release in the presence of lo are
reported in Figure 2. No Paf-acether was recovered after 48/80
stimulation. Rat kidneys immunized either with Ov in alumin-
ium hydroxide or in complete Freund's adjuvant also released
Paf-acether when challenged with Ov (Table 1). Paf-acether was
neither detected in the perfusion eluates, nor in the urinary
samples before the addition of agents.
Kidney Paf-acether fulfilled all the criteria of natural or
synthetic Paf-acether [23]. It aggregated aspirin-treated washed
rabbit platelets in the presence of CP/CPK. The activity was
destroyed by phospholipase A2 but not by lipase from Rhizopus
arrhizus. It resisted acid hydrolysis and was eluted from normal
pressure silicic acid chromatography in the first 100% methanol
fraction. The HPLC retention time of kidney Paf-acether was
the same as usually found for synthetic Paf-acether and was
I
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comprised between sphingomyelin and lysophosphatidyicho-
line which were used as markers (Fig. 3).
SRS release and characterization. SRS activity was not
detected when crude perfusion eluate from Jo-, 48/80-, and Ag-
challenged kidneys were assayed in guinea-pig ileum but only
after RP-HPLC purification (Fig. 4). SRS was eluted as two
major peaks corresponding to 36 and 61% methanol. The two
peaks coeluted with synthetic LTC and LTD. After perfusing
the kidney with [3H]AA and stimulation with the Jo, three peaks
of radioactivity were obtained on RP-HPLC. The major and
minor peaks comigrated with LTC and LTD, respectively (Fig.
5). The effluents corresponding to these two peaks demonstrat-
ed spasmogenic activity which was reversed by FPL 55712. The
large peak at 90 mm coeluted with synthetic AA.
Histamine and serotonin release. Neither histamine nor
serotonin were detected in the perfusate during the equilibra-
tion period (Fig. 6). The release began 2 mm after the addition
of Jo or 48/80, and "the plateau" was reached at 7 mm. The
total histamine and serotonin found in the perfusate at the end
of the perfusion is shown in Table 1.
Discussion
When rat kidneys were perfused with Ca2 Jo, Paf-acether,
SRS, histamine, and serotonin were released in the renal
venous vasculature. The release of SRS, histamine, and seroto-
nm but not that of Paf-acether was also obtained when kidneys
were challenged with compound 48/80. Paf-acether and SRS-A
were also released from antigen-stimulated kidneys from immu-
nized rats. To our knowledge, the present work is the first to
document the simultaneous release of four major mediators of
inflammation from the kidney. Circulating cells do not account
for the release of the mediators since (1) the kidneys were
extensively rinsed through blanching before being transferred
into the perfusion system, (2) the 1 x l0 leukocytes found in
the perfusate could not release the amount of Paf-acether found
in our samples [26], and (3) ultrastructural studies demonstrated
the absence of adhering blood elements in the kidney
vasculature.
In this study, the GFR of the perfused kidney was close to
normal, although slightly lower than that reported by other
invtstjontors [19. 201. This was not due to morphological
alterations of the kidneys which appeared optically or electron
microscopically unaltered.
The platelet-stimulating activity released from rat kidney was
identical to that obtained from hog leukocytes, and it was eluted
from HPLC exactly as synthetic Paf-acether. Blank et al [271
have proposed the 1-0-alkyl-2-acetyl-glyceryl-3-phosphorylcho-
line structure—that of Paf-acether—for the antihypertensive
polar renal medullary lipid. It was originally described by
Muirhead et al [28] and was extracted from murine and rabbit
renomedullary interstitial cells. Our present data now demon-
strate that, upon stimulation with the Ca2 Jo, isolated perfused
rat kidneys actively release in the renal venous system a
substance biochemically similar to the antihypertensive renal
lipid and Paf-acether. A role for Paf-acether in the pathogenesis
of kidney disease has been suggested in a variety of experimen-
tal and human studies U, 29—32]. It has also been reported that
rabbit kidney releases thromboxane A2, a cyclooxygenase-
dependent arachidonate metabolite, which is another potent
platelet aggregating and releasing agent [33]. Therefore, kidneys
are capable of releasing, by different metabolic pathways, two
soluble intermediates that are highly active on platelets.
too
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Fig. 5. RP-HPLC chromatogram of [3H1-labelled kidney products
obtained after 30 mm perfusion with 0.5 pCi of[3HJAA. Kidneys were
stimulated with lo as described in Methods. Samples were taken to
dryness and the residue was dissolved in distilled water for bio- and
radioactivity determination.
Time, mm
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Fig. 6. Kinetics of serotonin and histamine released from perfused rat
kidney upon stimulation with Jo (2.5 g/ml) I—. and 48/80 (10(hg/mI) 0—0.
Time, mm
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The release of SRS from sensitized perfused lung upon
antigenic challenge and from perfused cat paws upon 48/80
stimulation has already been reported [17, 34]. In our experi-
ments, this release was obtained from perfused rat kidney upon
addition of Jo, 48/80, or from sensitized kidney challenged with
Ov. However, the presence of spasmogenic activity in the
perfusate was only observed after several purification steps,
suggesting an SRS inhibitor in our starting samples. On RP-
HPLC, the spasmogenic activity was recovered in the fraction
where LTC and LTD were also found, indicating that the
kidney SRS could be related to the leukotriene structure. The
precursor role of AA for the kidney-derived SRS was confirmed
using radiolabeling experiments. Incorporation of labeled AA
into the SRS molecule was obtained by several authors working
on isolated cell systems [35—37]. Recently, 5, 8, 9 and 12
hydroxylated derivatives of AA were detected from several
isolated kidney cells [38—41] indicating the presence of a
lipoxygenase activity. However, the formation of leukotrienes
has never yet been reported. Whatever the precise molecular
structure of the compounds, our present results indicate the
secretion of an AA metabolite with spasmogenic activity in the
renal vasculature.
The similar kinetics and percentage of histamine and seroto-
nm release obtained upon Jo or 48/80 stimulation suggest a
similar cell origin for both mediators. These vasoactive amines
are well-defined rat mast cell markers [42], and 48/80 is a well
known mast cell degranulating agent [43]. Therefore, the re-
lease of histamine, serotonin and SRS by 48/80 strongly suggest
a mast cell origin, but the possibility that other renal cells could
be implicated in the release of SRS is not excluded. In contrast
with SRS, Paf-acether was not released upon challenge with
48/80. This probably excludes the rat kidney mast cells, a result
that agrees with the niacrophage as the only source for Paf-
acether in rat peritoneal cells [44]. Mononuclear leukocytes and
other phagocytic (mesangial) cells are intrinsic residents in
glomeruli [45, 46] raising the possibility that they could be
implicated in the release from the kidney of Paf-acether and
SRS [13, 14]. Finally, the release of Paf-acether and SRS from
sensitized kidney challenged with the specific antigen indicates
that this organ, as well as the lung, is able to undergo immuno-
logical reactions.
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